Literature DB >> 29055762

Percutaneous Coronary Intervention of Chronic Total Occlusions in Patients With Low Left Ventricular Ejection Fraction.

Alfredo R Galassi1, Marouane Boukhris2, Aurel Toma3, Zied Ibn Elhadj4, Lobna Laroussi4, Oliver Gaemperli5, Michael Behnes6, Ibrahim Akin6, Thomas F Lüscher5, Franz J Neumann3, Kambis Mashayekhi3.   

Abstract

OBJECTIVES: The study sought to assess the outcome of percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) in patients with low left ventricular ejection fraction (LVEF) (≤35%).
BACKGROUND: Data regarding the outcome of PCI in patients with low LVEF affected by CTO are scarcely reported.
METHODS: The authors performed a prospective longitudinal multicenter study including consecutive patients undergoing elective PCI of CTOs. Patients were subdivided into 3 groups: group 1 (LVEF ≥50%), group 2 (LVEF 35% to 50%), and group 3 (LVEF ≤35%).
RESULTS: A total of 839 patients (mean 64.6 ± 10.5 years of age, 87.7% men) underwent CTO PCI attempts. Baseline LVEF ≤35% was present in 72 (8.6%) patients. The angiographic success was high (overall 93.6%) and similar among the 3 groups (93.5% vs. 94.4% vs. 91.7%, respectively; all p = NS). In group 3, no periprocedural complications of CTO PCI were observed. Mean clinical follow-up of 16.3 ± 8.2 months duration was available in 781 (93.1%) patients including those with LVEF ≤35%. At 2 years, major cardiac and cerebrovascular events (MACCE) free survival was similar in the 3 groups (86% vs. 82.8% vs. 75.2%; all p = NS). In patients with LVEF ≤35%, LVEF improved significantly in the presence of a successful CTO PCI from 29.1 ± 3.4% to 41.6 ± 7.9% (p < 0.001).
CONCLUSIONS: In CTO patients with low LVEF, PCI could represent a safe and effective revascularization strategy achieving good midterm outcome and LVEF improvement.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PCI; chronic total occlusion; ischemic LV dysfunction; left ventricular ejection fraction

Mesh:

Year:  2017        PMID: 29055762     DOI: 10.1016/j.jcin.2017.06.058

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  16 in total

Review 1.  A contemporary review of clinical significances of percutaneous coronary intervention for chronic total occlusions, with some Japanese insights.

Authors:  Yoshihiro Morino
Journal:  Cardiovasc Interv Ther       Date:  2021-03-03

2.  Risk Burden of Coronary Perforation in Chronic Total Occlusion Recanalization: Latin American CTO Registry Analysis.

Authors:  Marcelo Harada Ribeiro; Carlos M Campos; Lucio Padilla; Antonio Carlos B da Silva; João Eduardo T de Paula; Marco Alcantara; Ricardo Santiago; Franklin Hanna; Franciele R da Silva; Karlyse C Belli; Lorenzo Azzalini; Pedro P de Oliveira; Gustavo N Araujo; Vincenzo Sucato; Kambis Mashayekhi; Alfredo R Galassi; Alexandre Abizaid; Alexandre Quadros
Journal:  J Am Heart Assoc       Date:  2022-06-03       Impact factor: 6.106

Review 3.  Role of Percutaneous Chronic Total Occlusion Interventions in Patients with Ischemic Cardiomyopathy and Reduced Left Ventricular Ejection Fraction.

Authors:  Nayef A Abouzaki; Jose E Exaire; Luis A Guzmán
Journal:  Curr Cardiol Rep       Date:  2018-10-01       Impact factor: 2.931

4.  Periprocedural and clinical outcomes of percutaneous coronary intervention of chronic total occlusions in patients with low- and mid-range ejection fractions.

Authors:  Waleed Salem El Awady; Mohamed Samy; Mohammad Mustafa Al-Daydamony; Magdy Mohammad Abd El Samei; Khaled Abd El Azim Shokry
Journal:  Egypt Heart J       Date:  2020-05-24

5.  Differential clinical impact of chronic total occlusion revascularization based on left ventricular systolic function.

Authors:  Hyungdon Kook; Jeong Hoon Yang; Jae Young Cho; Duck Hyun Jang; Min Sun Kim; Juneyoung Lee; Seung Hun Lee; Hyung Joon Joo; Jae Hyoung Park; Soon Jun Hong; Je Sang Kim; Hyun Jong Lee; Rak Kyeong Choi; Young Jin Choi; Jin Sik Park; Young Bin Song; Jin-Ho Choi; Joo-Yong Hahn; Hyeon-Cheol Gwon; Do-Sun Lim; Seung-Hyuk Choi; Cheol Woong Yu
Journal:  Clin Res Cardiol       Date:  2020-09-02       Impact factor: 5.460

Review 6.  Chronic total occlusion percutaneous coronary intervention in everyday clinical practice - an expert opinion of the Association of Cardiovascular Interventions of the Polish Cardiac Society.

Authors:  Leszek Bryniarski; Maksymilian P Opolski; Jarosław Wójcik; Maciej Lesiak; Tomasz Pawłowski; Jakub Drozd; Wojciech Wojakowski; Sławomir Surowiec; Maciej Dąbrowski; Adam Witkowski; Dariusz Dudek; Marek Grygier; Stanisław Bartuś
Journal:  Postepy Kardiol Interwencyjnej       Date:  2021-03-27       Impact factor: 1.426

7.  An Open (Up the Vessel) and Shut (Up the Critics) Case or Fake News?: Long-Term Outcomes Following Percutaneous Coronary Intervention of Chronic Total Occlusions.

Authors:  McCall Walker; Dharam J Kumbhani
Journal:  J Am Heart Assoc       Date:  2021-03-04       Impact factor: 5.501

Review 8.  Chronic total occlusion revascularization: A complex piece to "complete" the puzzle.

Authors:  Iacopo Muraca; Nazario Carrabba; Giacomo Virgili; Filippo Bruscoli; Angela Migliorini; Matteo Pennesi; Giulia Pontecorboli; Niccolò Marchionni; Renato Valenti
Journal:  World J Cardiol       Date:  2022-01-26

9.  Viability and functional recovery after chronic total occlusion percutaneous coronary intervention.

Authors:  Stefan P Schumacher; Henk Everaars; Wijnand J Stuijfzand; Pepijn A van Diemen; Roel S Driessen; Michiel J Bom; Ruben W de Winter; Yvemarie B O Somsen; Jennifer W Huynh; Ramon B van Loon; Peter M van de Ven; Albert C van Rossum; Maksymilian P Opolski; Alexander Nap; Paul Knaapen
Journal:  Catheter Cardiovasc Interv       Date:  2021-07-30       Impact factor: 2.585

10.  Long term clinical impact of successful recanalization of chronic total occlusion in patients with and without type 2 diabetes mellitus.

Authors:  Chuan-Tsai Tsai; Wei-Chieh Huang; Hsin-I Teng; Yi-Lin Tsai; Tse-Min Lu
Journal:  Cardiovasc Diabetol       Date:  2020-08-01       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.